ClinicalTrials.gg
RecruitingNCT07301034ZEPHYRUpdated Mar 11, 2026

A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack

A Phase 3 interventional study of Ziltivekimab and Ziltivekimab Placebo in Myocardial Infarction, sponsored by Novo Nordisk A/S. Recruiting at 20 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
332
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 140 studies in Myocardial Infarction with a site in Italy — 14 open to participants now, 25 under way, 6 of them phase 3. Myocardial Infarction · Italy.

Planned enrollment
56th of 101
332 · median 432
Started
2025
with 4 others
Phase 3
33 of 140
2 open now
Primary completion
2028-11
later than 18 of 24 live
Registered
139th of 140
by date

Among the 140 studies in Myocardial Infarction with a site in Italy, this one is the 56th largest by planned enrollment of the 101 interventional ones that give a count, is one of 5 that started in 2025, is one of 33 in phase 3, reaches primary completion later than 18 of the 24 other live ones, and was the 139th registered.

Myocardial Infarction

2,274 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

14 of the 140 studies in Myocardial Infarction with a site in Italy are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 140 studies in Myocardial Infarction with a site in Italy, or all of them as a file.
02

Study summary

The study is testing the effect of ziltivekimab on reducing plaque in the blood vessels of the heart, specifically aiming to manage or reduce atherosclerotic plaque. The purpose of the study is to determine whether ziltivekimab can effectively reduce this plaque. Participants will either receive ziltivekimab (the active medicine) or a placebo (a dummy medicine with no effect on the body), with the treatment assignment decided by chance. It is important to note that ziltivekimab is not yet approved in any country or region worldwide; therefore, it is a new medicine that doctors cannot prescribe. The study will last for about 15 months.

03

Conditions studied

  • Myocardial Infarction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  • Age 18 years or above at the time of providing informed consent.
  • Acute myocardial infarction, with at least one coronary segment (culprit lesion) treated with percutaneous coronary intervention (PCI):

    a. Acute ST-segment elevation myocardial infarction (STEMI) with all of the following: i. Onset of relevant pain suggestive of cardiac ischemia within less than or equal to (=\<) 24h of index angiography.

ii. (ECG)-changes (in the absence of left ventricular hypertrophy or left bundle branch block): ST-segment elevation at the J point in at least two contiguous leads greater than or equal to (>=) 0.25 millivolts (mV) in men less than (\<) 40 years, >=0.2 mV in men >=40 years, or >=0.15 mV in women in leads V2-V3; and/or >=0.1 mV in all other leads.

Non-ST segment elevation myocardial infarction (NSTEMI), with rise and/or fall in cardiac troponin I or T with at least one value above the 99th percentile upper reference limit.

  • At least two major native coronary arteries ‡ ("study vessels") each meeting the following criteria for intracoronary imaging immediately following the qualifying PCI procedure:

    1. Angiographic evidence of a reduction in lumen diameter between >20 and \<50 percent (%) by angiographic visual estimation.
    2. Study vessel deemed to be accessible to imaging catheters and suitable for intracoronary imaging in the proximal (50 millimeter [mm]) segment ("study segment").
    3. Study vessel may not be a bypass (saphenous vein or arterial) graft or a bypassed native vessel.
    4. Study vessel must not have undergone previous PCI within the study segment.
    5. A vessel which is candidate for intervention at the time of qualifying PCI or over the following 6 months in the judgment of the Investigator, cannot be a study vessel.

      5. Hemodynamic stability (as assessed by the treating physician) allowing the repetitive administration of nitroglycerine during the study specific imaging procedure.

      6. Ability to understand the requirements of the study and to provide informed consent 7. Willingness to undergo follow-up intracoronary imaging. 8. Possibility for randomisation and administration of the loading dose as early as possible after invasive procedure and latest within 48 hours after index PCI.

      Two study segments may be obtained in the same vessel (e.g. two study segments in the Right Coronary Artery [RCA] or Left Circumflex Artery [LCX]), at the investigators discretion, considering vessel anatomy (e.g. left or right dominance), and where suitable landmarks between segments are at least 40 mm apart and with vessel wall irregularities.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to study intervention(s) or related products.
  • Known allergy to contrast medium, heparin, aspirin, ticagrelor or prasugrel.
  • Previous participation in this study. Participation is defined as randomisation.
  • Female of .
  • Participation in any other interventional or imaging clinical study within the past 30 days, or as parallel inclusion during the index hospitalization.
  • Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
  • Left-main disease, defined as >=50 percent (%) reduction in lumen diameter of the left main coronary artery by angiographic visual estimation
  • Three-vessel disease, defined as the presence of severe or significant coronary artery disease (CAD) on the basis of angiography, imaging, or physiology, in all three major epicardial territories (including major branches) that have an indication for revascularization or are too advanced to be treated.
  • History of coronary artery bypass surgery
  • Thrombolysis In Myocardial Infarction (TIMI) flow \<2 of the infarct-related artery after PCI
  • Unstable clinical status (hemodynamic or electrical instability. Hemodynamic instability defined as any of the following:

Killip Class III or IV. Sustained and/or symptomatic hypotension (as assessed by the treating physician).

  • Significant coronary calcification or tortuosity deemed to preclude Intra-Vascular Ultrasound (IVUS), Near Infrared Spectroscopy (NIRS) and Optical Coherence Tomography (OCT) evaluation.
  • Uncontrolled cardiac arrhythmia, defined as recurrent and symptomatic ventricular tachycardia or atrial fibrillation with rapid ventricular response not controlled by medications in the past 3 months prior to screening.
  • Severe kidney impairment defined as any of the following:

Previous or current estimated \<30 milliliters per minute (ml/min) /1.73 square meter (m\^2) Chronic haemodialysis or peritoneal dialysis.

- Active liver disease or hepatic dysfunction defined as at least one of the following: Previously known or current hepatic encephalopathy (clinical evaluation) Previously known or current ascites (clinical evaluation) Jaundice (clinical evaluation) Previous oesophageal/gastric variceal bleeding Known hepatitis cirrhosis

  • Current use of anti-interleukin (IL)-6 products or anticipated use of such drugs any time during the study.
  • Use of systemic drugs (both small molecules and biologics) or disease modifying anti-rheumatic drugs (DMARDs including both biologic DMARDs like anti- TNFalpha and conventional DMARDs like methotrexate) or anticipated chronic use of such drugs any time during the study. (Note: Use of otic, ophthalmic, inhaled, and topical or local corticosteroid injections are not exclusionary. Furthermore, temporary systemic immunosuppressive treatment of e.g., [COPD] exacerbations is allowed).
  • Known, or suspicion of, active infection or major hematologic, metabolic, or endocrine dysfunction in the judgment of the Investigator.
  • History of recurrent serious infections (infections leading to hospitalization or use of intravenous (i.v.) antibiotics) within the past 12 months, at the discretion of the investigator.
  • Use of preventive systemic antibiotics, systemic antivirals, or systemic antifungals (Note: "Systemic" is defined as oral or i.v. drugs that are absorbed into the circulation. Antibiotics used to treat latent TB are exempted).
  • \<2x10 10\^9/L
  • Absolute count \< 120 x10\^9/L
  • (ALT) or aspartate aminotransferase (AST) >8 × . Participants with increased levels of ALT or AST \<=8 x upper limit of normal (ULN) are eligible at the discretion of the investigator if the investigator considers the ALT or AST elevations to be caused by the current AMI. In case the elevation is considered related to other reasons than the current AMI, participants should be excluded when ALT or AST >2.5 x(ULN).
  • Known (acute or chronic) or
  • Planned surgery within 12 months from the time of screening.
  • History of cancer within the past 5 years, except for adequately treated basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, low risk prostate cancer, or carcinoma in situ/high grade prostatic intraepithelial neoplasia (PIN) at the discretion of the investigator.
  • Estimated less than 2 years
  • Presence of risk factors for tuberculosis (TB) or history or evidence of latent TB such as (but not limited to):

History or evidence of a positive TB test or chest X-ray compatible with latent TB and TB treatment initiated less than 28 days prior to randomisation.

  • Diagnosis of (HIV).
  • History of gastrointestinal perforation (Note: History of perforated appendicitis more than 5 years old is not exclusionary).
  • History of active diverticulitis within the past 5 years.
  • History of inflammatory bowel disease that has been clinically active within the past 12 months.
  • History of bone marrow or solid organ transplant or anticipated to receive an organ transplant during the study.
  • Received a live or attenuated- product within 4 weeks of study intervention administration or expected to receive a live or attenuated-live vaccine product during the treatment period.
  • Major cardiac surgical (including but not restricted to coronary artery bypass graft surgery [CABG]), non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days or any major surgical procedure planned at the time of randomisation or as treatment for the current AMI (CABG).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
332 participants (estimated)

Study arms

  • Experimental
    Ziltivekimab dose level 1 + standard of care (SOC)

    Participants receive dose level 1 of ziltivekimab along with standard of care (SOC) subcutaneously once monthly for 12 months.

    Drug: Ziltivekimab

  • Placebo comparator
    Placebo + SOC

    Participants receive a placebo along with standard of care (SOC) subcutaneously once monthly for 12 months.

    Drug: Ziltivekimab Placebo

Interventions

  • Participants will receive ziltivekimab subcutaneously.

  • DrugZiltivekimab Placebo

    Participants will receive placebo matched to ziltivekimab subcutaneously.

06

What researchers measure

Primary outcomes

  1. Change in percent atheroma volume (PAV) as determined by greyscale intravascular ultrasound (IVUS) in matched regions of interest

    Percentage (%).

    Time frame: From randomisation (week 0) to end-of-study (52-week)

Secondary outcomes

  1. Change in maximum lipid core burden index (LCBI) in any 4-mm segment(maxLCBI4mm) as determined by Near-infrared spectroscopy (NIRS) in matched regions of interest

    Lipid core burden index (LCBI) (0 to 1000).

    Time frame: From randomisation (week 0) to end-of-study (52-week)

  2. Change in minimal fibrous cap thickness as determined by (optical coherence tomography) OCT in matched regions of interest

    Micro meter (µmeter).

    Time frame: From randomisation (week 0) to end-of-study (52-week)

  3. Change in lipid core burden index (LCBI) total as determined by NIRS in matched regions of interest

    LCBI index (0 to 1000).

    Time frame: From randomisation (week 0) to end-of-study (52-week)

  4. Change in average angular extension (AAE) of macrophages as determined by OCT in matched regions of interest

    Degrees (°).

    Time frame: From randomisation (week 0) to end-of-study (52-week)

  5. Change in normalized total atheroma volume (NTAV) by IVUS in matched regions of interest

    Cubic Millimeter (mm3).

    Time frame: From randomisation (week 0) to end-of-study (52-week)

  6. Change in mean fibrous cap thickness as determined by OCT in matched region of interest

    µmeter.

    Time frame: From randomisation (week 0) to end-of-study (52-week)

  7. Change in interleukin6 (IL-6)

    Picograms per milliliter (pg/mL).

    Time frame: From randomisation (week 0) to week 4, and week 52

  8. Change in high-sensitivity C-reactive protein (hs-CRP)

    Milligrams per deciliter (mg/dL).

    Time frame: From randomisation (week 0) to week 4, and week 52

  9. Change in high-sensitivity Troponin T (hs-TnT)

    Nanograms per milliliter (ng/mL).

    Time frame: From randomisation (week 0) to week 4, and week 52

  10. Change in N-terminal-pro-brain natriuretic peptide (NT-pro-BNP)

    Picograms per milliliter (pg/mL).

    Time frame: From randomisation (week 0) to week 4, and week 52

  11. Change in lipid and inflammatory markers

    Time frame: From randomisation (week 0) to week 4, and week 52

  12. Time to first occurrence of: All-cause death

    Number of first occurrences and time-to-event.

    Time frame: From randomisation (week 0) to end-of-study (52 weeks)

  13. Time to first occurrence of: Cardiac death

    Number of first occurrences and time-to-event.

    Time frame: From randomisation (week 0) to end-of-study (52-week)

  14. Time to first occurrence of:Non-fatal spontaneous myocardial infarction

    Number of first occurrences and time-to-event.

    Time frame: From randomisation (week 0) to end-of-study (52-week)

  15. Time to first occurrence of: Any coronary revascularization

    Number of first occurrences and time-to-event.

    Time frame: From randomisation (week 0) to end-of-study (52-week)

  16. Time to first occurrence of: Non-fatal stroke

    Number of first occurrences and time-to-event.

    Time frame: From randomisation (week 0) to end-of-study (52-week)

  17. Time to first occurrence of:Transient ischemic attack

    Number of first occurrences and time-to-event.

    Time frame: From randomisation (week 0) to end-of-study (52-week)

07

Study locations

3 of 20 sites recruiting
  • Medizinische Universität Wien
    Vienna, 1090, Austria
    Not yet recruiting
  • Aalborg Universitetshospital Hjertemedicinsk Afdeling
    Gistrup, 9260, Denmark
    Not yet recruiting
  • Rigshospitalet - Kardiologisk Forskningsenhed
    København Ø, 2100, Denmark
    Not yet recruiting
  • Azienda Ospedaliera San Giovanni Addolorata
    Rome, Lazio 00184, Italy
    Not yet recruiting
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
    Bergamo, Lombardy 24127, Italy
    Not yet recruiting
  • DAI Scienze Mediche - UOC Endocrinologia
    Messina, Sicily 98124, Italy
    Not yet recruiting
  • Presidio Ospedaliero di Rivoli
    Rivoli, To 10098, Italy
    Not yet recruiting
  • Ospedale Policlinico San Martino
    Genova, 16132, Italy
    Not yet recruiting
  • AOU Maggiore della Carità di Novara - Dipartimento Toraco-Cardio-Vascolare - SCDU Cardiologia
    Novara, 28100, Italy
    Not yet recruiting
  • Azienda Ospedaliera Universitaria San Luigi Gonzaga - S.C.D.O. Microcitemie e malattie rare ematologiche
    Orbassano, 10043, Italy
    Not yet recruiting
  • Fondazione Policlinico Universitario Agostino Gemelli IRCS
    Rome, 00168, Italy
    Not yet recruiting
  • IRCCS Policlinico San Donato
    San Donato Milanese, 20097, Italy
    Not yet recruiting
  • Radboudumc
    Nijmegen, 6525 GA, Netherlands
    Not yet recruiting
  • Erasmus MC
    Rotterdam, 3015 GD, Netherlands
    Not yet recruiting
  • Hospital Universitario de la Princesa
    Madrid, 28006, Spain
    Not yet recruiting
  • Hospital Universitario Marqués de Valdecilla
    Santander, 39008, Spain
    Not yet recruiting
  • Universitäres Herzzentrum
    Basel, 4031, Switzerland
    Recruiting
  • Inselspital-Universitätsklinik für Kardiologie
    Bern, 3010, Switzerland
    Recruiting
  • HUG-Service de Cardiologie
    Geneva, 1205, Switzerland
    Not yet recruiting
  • LUKS-Herzzentrum
    Lucerne, 6000, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Nov 2028, 34 months after the start.

Of 57 phase 3 interventional studies under Myocardial Infarction, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 77. This study's planned 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Dec 24, 2025
StartActual
Dec 18, 2025
Primary completionEst.
Nov 14, 2028
CompletionEst.
Feb 24, 2029
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07301034
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Dec 18, 2025
Primary completion
Nov 14, 2028 (estimated)
Completion
Feb 24, 2029 (estimated)
Last update
Mar 11, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziltivekimab

Start the discussion